NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-08-31
Reading HUM? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Maintain EPS guidance of at least $9.00 for FY 2026: EPS guidance $9.00 vs $9.00 target (LOWERED).
Humana keeps its EPS guidance at $9.00 for 2026. It won a big Illinois Medicaid contract that should boost revenue and margins. The company also announced a share buyback program, showing strong capital allocation. Recent earnings beats support steady profit growth.
EPS guidance is soft and behind targets. Net income declined sharply in late 2025. Management is volatile, and capital obligations have increased. These risks could pressure margins and growth.
The price is about 21% above our fair value near $322. Analysts expect 16% revenue growth. Our fair value is 24% above the Street median, reflecting confidence in Humana's growth and margin outlook.
Breaks if: Buyback program is halted or materially reduced
Breaks if: EPS guidance falls below $9.00 for FY 2026
Revenue growth falls below 15% YoY in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on healthcare services. The current thesis state is intact, supported by strong recent financial performance despite some volatility in management execution and elevated risks.
The market currently prices HUM as cheap compared to its peers, reflecting a low expectations gap. There is a sense of fragility in execution quality, but the overall valuation appears justified given the company's recent performance.
Fundamentals are likely to remain strong in the near term, as management has consistently prioritized maintaining adjusted EPS guidance and expanding key platforms. However, risks related to regulatory challenges and the impact of Star Ratings on earnings could create headwinds.
The thesis hinges on several factors, including the potential for management to reverse course and raise guidance, the performance of sector bellwethers, and the overall health of the jobs market. These elements will be crucial in determining HUM's trajectory moving forward.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the thesis, showing strong performance. However, next quarter's revenue guidance is below consensus, which weakens expectations. The impact of Star Ratings on Medicare Advantage remains a concern, posing additional challenges.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, HUM's performance will depend on its ability to navigate regulatory challenges and capitalize on sector momentum. Not investment advice.
